{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:46:33Z","timestamp":1795088793698,"version":"4.10.2"},"reference-count":18,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.284793","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:27:36Z","timestamp":1708576056000},"page":"2372-2377","source":"Crossref","is-referenced-by-count":3,"title":["Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses"],"prefix":"10.3324","volume":"109","author":[{"given":"Mehmet H.","family":"Kocoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton C.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"63881","doi-asserted-by":"crossref","unstructured":"Atanackovic D, Luetkens T, Omili D. Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. Blood. 2022; 140(2):152-156.","DOI":"10.1182\/blood.2022016175"},{"key":"63882","doi-asserted-by":"crossref","unstructured":"Dahiya S, Luetkens T, Lutfi F. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy. Blood Adv. 2022; 6(2):686-689.","DOI":"10.1182\/bloodadvances.2021006112"},{"key":"63883","doi-asserted-by":"crossref","unstructured":"Atanackovic D, Kreitman RJ, Cohen J. T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. J Immunother Cancer. 2022; 10(7):e004953.","DOI":"10.1136\/jitc-2022-004953"},{"key":"63884","doi-asserted-by":"crossref","unstructured":"Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018; 2(12):1495-1509.","DOI":"10.1182\/bloodadvances.2017008375"},{"key":"63885","doi-asserted-by":"crossref","unstructured":"Nauffal M, Kim HT, Richardson PG. Defibrotide: real-world management of veno-occlusive disease\/sinusoidal obstructive syndrome after stem cell transplant. Blood Adv. 2022; 6(1):181-188.","DOI":"10.1182\/bloodadvances.2021005410"},{"key":"63886","doi-asserted-by":"crossref","unstructured":"Eissner G, Hartmann I, Kesikli A. CD4+CD25+FoxP3+ regulatory T cells enhance the allogeneic activity of endothelial-specific CD8+\/CD28-CTL. Int Immunol. 2011; 23(8):485-492.","DOI":"10.1093\/intimm\/dxr041"},{"key":"63887","doi-asserted-by":"crossref","unstructured":"Strouse C, Richardson P, Prentice G. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016; 22(7):1306-1312.","DOI":"10.1016\/j.bbmt.2016.04.011"},{"key":"63888","doi-asserted-by":"crossref","unstructured":"Palomo M, Mir E, Rovira M, Escolar G, Carreras E, Diaz-Ricart M. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood. 2016; 127(13):1719-1727.","DOI":"10.1182\/blood-2015-10-676114"},{"key":"63889","doi-asserted-by":"crossref","unstructured":"Francischetti IM, Oliveira CJ, Ostera GR. Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler Thromb Vasc Biol. 2012; 32(3):786-798.","DOI":"10.1161\/ATVBAHA.111.240291"},{"key":"63890","doi-asserted-by":"crossref","unstructured":"Fernandez S, Palomo M, Molina P. Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender. J Thromb Haemost. 2021; 19(8):1948-1958.","DOI":"10.1111\/jth.15343"},{"key":"63891","doi-asserted-by":"crossref","unstructured":"Elhadad S, Redmond D, Tan A. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb Res. 2023; 225:47-56.","DOI":"10.1016\/j.thromres.2023.03.009"},{"key":"63892","doi-asserted-by":"crossref","unstructured":"Barnes BJ, Adrover JM, Baxter-Stoltzfus A. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020; 217(6):e20200652.","DOI":"10.1084\/jem.20200652"},{"key":"63893","doi-asserted-by":"crossref","unstructured":"Shi H, Gandhi AA, Smith SA. Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. JCI Insight. 2021; 6(17):e149149.","DOI":"10.1172\/jci.insight.149149"},{"key":"63894","doi-asserted-by":"crossref","unstructured":"Ali RA, Estes SK, Gandhi AA. Defibrotide inhibits antiphospholipid antibody-mediated neutrophil extracellular trap formation and venous thrombosis. Arthritis Rheumatol. 2022; 74(5):902-907.","DOI":"10.1002\/art.42017"},{"key":"63895","doi-asserted-by":"crossref","unstructured":"Onuora S. Defibrotide inhibits NET-mediated thrombosis in APS models. Nat Rev Rheumatol. 2022; 18(2):63.","DOI":"10.1038\/s41584-021-00742-8"},{"key":"63896","doi-asserted-by":"crossref","unstructured":"Frame D, Scappaticci GB, Braun TM. Defibrotide therapy for SARS-CoV-2 ARDS. Chest. 2022; 162(2):346-355.","DOI":"10.1016\/j.chest.2022.03.046"},{"key":"63897","doi-asserted-by":"crossref","unstructured":"Garcia-Bernal D, Palomo M, Martinez CM. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. J Cell Mol Med. 2020; 24(14):8031-8044.","DOI":"10.1111\/jcmm.15434"},{"key":"63898","doi-asserted-by":"crossref","unstructured":"Richardson E, Garcia-Bernal D, Calabretta E. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin Ther Targets. 2021; 25(6):423-433.","DOI":"10.1080\/14728222.2021.1944101"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284793\/76636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284793\/77236","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11471\/76636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:46Z","timestamp":1794045946000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284793","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}